Alcon Inc.'s strong growth, strategic acquisitions, and market leadership highlight its long-term potential. Read more on ALC ...

Fast-tracked cross-appeals in Delaware by Alcon Research LLC and Aurion Biotech Inc. have been closed, now that Alcon has bought a majority stake in the company that’s developing a potentially ...

The founder of menopause startup Gennev steps down, while the CEO and founder of Aurion Biotech is pushed out, plus other ...

Kunst was ousted from the Seattle-based Aurion after Swiss eye-care giant Alcon acquired a majority interest in the company March 26. He tried buying new skis and golf clubs since the takeover ...

Alcon: Within its Surgical business ... To progress with cell therapy, the company recently acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell ...

Alcon scored a strong price increase driven by the optimism surrounding the company’s aggressive move on the M&A front. The company recently acquired a majority interest in Aurion Biotech ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Needham raised the firm’s price target on Alcon (ALC) to $110 from $107 and keeps a Buy rating on the shares. Following the company’s Capital Markets Day, the firm has come away more confident ...

The Aurion board appointed Arnaud Lacoste, PhD, as CEO. Editor’s note: This is a developing news story. Please check back soon for updates. Alcon has acquired a majority interest in Aurion ...

Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.